October 1, 2026
CMIC Co., Ltd.
Announcement of Change in President
CMIC Co., Ltd. hereby announces that, effective October 1, 2026, Takanobu Yoshida, currently Vice President and Chief Financial Officer (CFO), will succeed Shuji Katayama as President.
Background to the Appointment of the New President
The pharmaceutical development and healthcare industry in which CMIC operates is undergoing a period of significant transformation.
In response to these changes, CMIC has decided to transition to a new management structure to further accelerate business growth and enhance long-term corporate value.
Since entering into a strategic capital partnership in the CRO business in 2025 between CMIC HOLDINGS Co., Ltd. and a private equity fund managed by Blackstone Inc. and its affiliates, CMIC has been actively pursuing its growth strategy.
Going forward, CMIC will continue to strengthen its support for pharmaceutical and biotechnology companies both in Japan and internationally, while contributing to the advancement of the pharmaceutical development environment in Japan.
Message from the New President Takanobu Yoshida
I am honored to assume the role of President of CMIC Co., Ltd.
CMIC has long contributed to the advancement of medical care and healthcare as a trusted partner supporting the development of pharmaceuticals and medical devices, underpinned by our commitment to quality and deep expertise. As Vice President and CFO, I have focused on strengthening our business foundation and driving sustainable growth, while building a robust management platform that enables us to continue earning the trust of our clients.
Building on the trust and proven track record we have cultivated over the years, we will further enhance our quality, expertise, and problem-solving capabilities to meet the evolving needs and expectations of our clients amid the rapidly changing healthcare landscape.
We will also continue pursuing our vision of “Bringing Global Clinical Trials to Japan, With the Power of CMIC.” To bring this vision to life, we will further strengthen our collaboration with pharmaceutical and biotechnology companies around the world and contribute to enhancing Japan’s drug development ecosystem and improving patient access to innovative therapies.
At the heart of everything we do is our commitment to creating a better future for patients. Together with our employees, we will continue to embrace new challenges so that patients in need of innovative treatments can gain access to new therapeutic options as quickly as possible.
Biography of Takanobu Yoshida
February 2009 Joined JCL Bioassay Co., Ltd.
March 2015 Appointed Executive Representative Director and Vice President, JCL Bioassay Co., Ltd.
October 2015 Appointed Executive Vice President, CMIC Pharma Science Co., Ltd.
October 2018 Appointed Corporate Officer and General Manager, Finance & Accounting Department, CMIC HOLDINGS Co., Ltd.
October 2022 Appointed Executive Vice President and Chief Financial Officer (CFO), CMIC Co., Ltd.
October 2026 (scheduled) President, CMIC Co., Ltd.
About CMIC Co., Ltd.
CMIC Co., Ltd., as the core company responsible for the CRO business within the CMIC Group, provides comprehensive support for pharmaceutical development through a broad range of services, including clinical trial consulting, monitoring, data management, biostatistics, and safety management, as well as regulatory submission support, post‑marketing surveillance (PMS), and database research. In addition to global capabilities, the company actively adopts digital technologies and new methodologies to deliver highly reliable development support that balances enhanced efficiency with improved quality.
